Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERELZI vs ENBREL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erelzi (etanercept-szzs) is a tumor necrosis factor (TNF) blocker. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) TNF receptor linked to the Fc portion of human Ig G1. Erelzi binds specifically to TNF-alpha and blocks its interaction with cell surface TNF receptors, thereby reducing TNF-mediated inflammatory responses.
Tumor necrosis factor (TNF) inhibitor; etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of human TNF receptor p75 linked to the Fc portion of human Ig G1. It binds to soluble and membrane-bound TNF, thereby blocking TNF-mediated inflammatory responses.
Rheumatoid arthritis (moderately to severely active),Polyarticular juvenile idiopathic arthritis (moderate to severe),Psoriatic arthritis,Ankylosing spondylitis,Plaque psoriasis (chronic moderate to severe)
Rheumatoid arthritis (moderate to severe active RA in adults, alone or with methotrexate),Polyarticular juvenile idiopathic arthritis (moderate to severe active JIA in patients aged 2 years and older),Psoriatic arthritis (active Ps A in adults),Ankylosing spondylitis (active AS in adults),Plaque psoriasis (moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy)
For plaque psoriasis: 100 mg subcutaneous injection once weekly, after initial loading dose of 200 mg at weeks 0, 1, 2, 3, and 4. For psoriatic arthritis: 100 mg subcutaneous injection once weekly.
50 mg subcutaneous injection once weekly
Terminal elimination half-life: 13–16 days (mean 14.6 days) in adults with moderate-to-severe plaque psoriasis; clinical context: supports every-2-week subcutaneous dosing regimen.
Approximately 102 hours (range 68–170 hours) after subcutaneous administration in adults; prolonged in elderly and patients with renal impairment; supports every 2-week dosing.
Erelzi is a monoclonal antibody-based fusion protein. It is expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes have been identified; it is not metabolized by cytochrome P450 enzymes.
Metabolism is via peptide hydrolysis and protein catabolism; no significant cytochrome P450 involvement.
Renal: negligible (not significantly excreted unchanged); Biliary/Fecal: primary elimination pathway via proteolytic catabolism to amino acids; approximately 95% of dose recovered as small peptides/amino acids in feces.
Renal: negligible; Biliary/Fecal: not significantly eliminated; primarily degraded via proteolysis into amino acids.
Approximately 95–98% bound; primarily to endogenous immunoglobulins (Ig G) via Fc Rn binding; minimal binding to albumin or other plasma proteins.
~96% bound, primarily to albumin and to a lesser extent to other plasma proteins.
Volume of distribution: 3.5–4.0 L (approximately 0.05 L/kg for a 70 kg adult), indicating limited extravascular distribution, predominantly confined to vascular space and interstitial fluid.
Approximately 0.18 L/kg (adults), indicating limited distribution primarily within the vascular and interstitial spaces; not extensively distributed into tissues.
Subcutaneous: absolute bioavailability approximately 75–80% following injection into thigh, abdomen, or upper arm.
Subcutaneous: approximately 59% (range 50–76%) after a single 25 mg dose; absolute bioavailability not established for IV route; intramuscular route not recommended.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²); use with caution.
No dose adjustment required for renal impairment. Not studied in patients with severe renal impairment.
No formal studies in hepatic impairment. Use with caution in Child-Pugh Class B or C due to potential altered clearance.
No dose adjustment required for hepatic impairment. Not studied in patients with severe hepatic impairment.
Safety and efficacy not established in pediatric patients <18 years old; no approved dosing.
For juvenile idiopathic arthritis (JIA) patients aged 2 years and older: 0.8 mg/kg (max 50 mg) subcutaneously once weekly.
No specific dose adjustment recommended based on age alone; monitor for adverse effects due to potential age-related decreases in renal function.
No specific dose adjustment based on age alone; monitor for infections and adverse effects as elderly patients may have increased susceptibility.
WARNING: SERIOUS INFECTIONS AND MALIGNANCY. Patients treated with TNF blockers, including Erelzi, are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue Erelzi if a patient develops a serious infection. Reported infections include: active tuberculosis (including reactivation of latent TB), invasive fungal infections (e.g., histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis), and bacterial, viral, or other opportunistic infections. Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers.
Serious infections, including tuberculosis (TB), invasive fungal infections, and other opportunistic infections, have been reported. Patients should be screened for TB prior to therapy. Discontinue if serious infection develops. Malignancies, including lymphoma, have been reported in children and adolescents treated with TNF blockers.
Serious infections: Do not start Erelzi in patients with active infections. Monitor for signs/symptoms of infection during treatment.,Malignancies: Risk of lymphoma and other malignancies; higher in children and adolescents.,Hepatitis B reactivation: Screen for HBV before starting therapy; discontinue if reactivation occurs.,Demyelinating disorders: Rare cases of CNS demyelinating disorders (e.g., multiple sclerosis, optic neuritis) reported; use caution in patients with pre-existing or recent-onset demyelinating disorders.,Congestive heart failure: Use caution in patients with heart failure; discontinue if new or worsening symptoms occur.,Hematologic events: Pancytopenia, aplastic anemia reported; advise patients to seek medical attention if signs of blood dyscrasias develop.,Hypersensitivity: Serious allergic reactions (including anaphylaxis) have been reported; discontinue if reaction occurs.,Immunizations: Avoid live vaccines during therapy.
Risk of serious infections (including TB, bacterial sepsis, invasive fungal infections),Hepatitis B reactivation,Malignancies (including lymphoma, leukemia, and other malignancies),Congestive heart failure (new onset or exacerbation),Demyelinating disorders (e.g., multiple sclerosis, optic neuritis),Hematologic abnormalities (including pancytopenia and aplastic anemia),Hypersensitivity reactions,Live vaccines should not be administered concurrently
Severe infections including sepsis,Known hypersensitivity to etanercept or any component of the product
Known hypersensitivity to etanercept or any component of the product,Sepsis or active infections (including chronic or localized infections)
No known food interactions. Grapefruit and other foods do not affect bimekizumab. However, maintain a balanced diet. If you have a history of liver disease, follow any dietary recommendations provided by your healthcare provider, but there are no specific restrictions.
No specific food interactions have been reported with ENBREL. However, because ENBREL affects the immune system, patients should practice food safety to reduce infection risk (e.g., avoid undercooked meats, unpasteurized dairy).
Pregnancy Category N. No adequate animal reproduction studies. No well-controlled human studies. At therapeutic doses, immunomodulatory effects may theoretically increase risk of pregnancy loss and congenital anomalies. First trimester exposure: unknown teratogenic risk. Second and third trimester: potential for adverse fetal immune effects.
Etanercept is an Ig G1 fusion protein that undergoes active placental transfer, increasing from the first to third trimester. Limited human data show no clear increase in major birth defects or miscarriage, but there is a potential for immunosuppression in the neonate if used in the third trimester. Animal studies show no teratogenicity.
No data on presence in breast milk. M/P ratio unknown. Maternal Ig G is known to be excreted in breast milk; as a monoclonal antibody, Erelzi may be present. Caution recommended, especially in preterm infants or those with compromised gastrointestinal barrier.
Etanercept is excreted into breast milk in low amounts (M/P ratio approximately 0.001). Oral bioavailability is poor due to protein nature, so infant exposure is minimal. Compatible with breastfeeding, but monitor infant for infection or other adverse effects.
No established dose adjustments for pregnancy. Pharmacokinetics of monoclonal antibodies may change due to increased plasma volume and altered metabolism. Consider therapeutic drug monitoring if available, but lack of data precludes specific dose changes.
No standard dose adjustment recommended. However, due to increased clearance in later pregnancy, some clinicians may consider increasing dose or shortening interval to maintain efficacy, especially in the third trimester.
ERELZI (bimekizumab) is a humanized monoclonal Ig G1 antibody that selectively inhibits IL-17A and IL-17F. For plaque psoriasis, consider loading dose: 320 mg (two 160 mg injections) subcutaneously at weeks 0, 4, 8, then 320 mg every 8 weeks. Monitor for hypersensitivity reactions and infections. May elevate liver enzymes; check baseline and periodic LFTs. Avoid live vaccines. Can be used with caution in patients with history of inflammatory bowel disease. Injection site reactions are common; rotate sites. Not recommended in pregnancy unless benefit outweighs risk.
ENBREL (etanercept) is a TNF-alpha inhibitor used for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and polyarticular juvenile idiopathic arthritis. Monitor for infections, including tuberculosis reactivation. Do not administer live vaccines during therapy. Injection site reactions are common. If switching from other TNF inhibitors, consider washout period. ENBREL can be used in combination with methotrexate but avoid with other biologics.
ERELZI is given as an injection just under the skin; you or a caregiver can be trained to inject at home.,Store in refrigerator at 36°F to 46°F (2°C to 8°C); do not freeze. Protect from light. Let it sit at room temperature for 30 minutes before injecting.,Do not use if solution is cloudy, discolored, or contains particles.,Tell your doctor if you have any signs of infection (fever, chills, cough, painful urination) or allergic reaction (rash, itching, difficulty breathing).,Avoid live vaccines during treatment.,You may need blood tests to check your liver function before and during treatment.,Seek medical attention if you develop symptoms of inflammatory bowel disease (new or worsening abdominal pain, diarrhea, blood in stool).
ENBREL is given as a subcutaneous injection, typically once or twice weekly. Proper injection technique and rotation of sites are important.,Do not take live vaccines (e.g., MMR, nasal flu, varicella) while on ENBREL.,Seek medical attention if you develop signs of infection (fever, chills, cough) or allergic reactions (rash, difficulty breathing).,Report any new or worsening neurological symptoms, such as numbness, tingling, or vision changes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERELZI vs ENBREL, answered by our medical review team.
ERELZI is a TNF-alpha Inhibitor that works by Erelzi (etanercept-szzs) is a tumor necrosis factor (TNF) blocker. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) TNF receptor linked to the Fc portion of human Ig G1. Erelzi binds specifically to TNF-alpha and blocks its interaction with cell surface TNF receptors, thereby reducing TNF-mediated inflammatory responses.. ENBREL is a TNF-alpha Inhibitor that works by Tumor necrosis factor (TNF) inhibitor; etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of human TNF receptor p75 linked to the Fc portion of human Ig G1. It binds to soluble and membrane-bound TNF, thereby blocking TNF-mediated inflammatory responses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERELZI and ENBREL depend on the specific clinical indication. These are both TNF-alpha Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERELZI is: For plaque psoriasis: 100 mg subcutaneous injection once weekly, after initial loading dose of 200 mg at weeks 0, 1, 2, 3, and 4. For psoriatic arthritis: 100 mg subcutaneous injection once weekly.. The standard adult dose of ENBREL is: 50 mg subcutaneous injection once weekly. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERELZI and ENBREL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERELZI is classified as Category C. Pregnancy Category N. No adequate animal reproduction studies. No well-controlled human studies. At therapeutic doses, immunomodulatory effects may theoretically increase risk of p. ENBREL is classified as Category C. Etanercept is an IgG1 fusion protein that undergoes active placental transfer, increasing from the first to third trimester. Limited human data show no clear increase in major birt. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.